ArticleMolecular neurobiology2025
Single-Cell Sequencing Screening of Biomarkers Associated with Lipophagy in the MPTP Model Mice of Parkinson's Disease.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Lipophagy may play an antioxidant and protective role in the pathogenesis of Parkinson's disease (PD). However, the specific mechanism of lipophagy in PD is rarely reported. MPTP model mice brains (PD, n = 3; CON, n = 3) underwent scRNA-seq. Post-QC, cells were clustered and annotated. Differential infiltrated cells (DICs) were identified between PD and CON. DICs were further sub-clustered. DIC-DEGs and DE-LRGs were determined. Overlapping DIC-DEGs and DE-LRGs yielded candidate genes. CytoNCA's five algorithms screened biomarkers. Biomarker expression was compared between PD and CON. Cell-cell communication and pseudotime analyses explored communication and differentiation. In scRNA-seq, 28 distinct clusters were annotated with seven known cell types, including oligodendrocytes, astrocytes, and neurons. Among them, the DICs, oligodendrocytes, and neurons were clustered into six and seven distinct cell subclusters, respectively. Importantly, a total of 241 DIC-DEGs and 664 DEGs were identified, followed by generating 179 candidate genes. Ubb, Gapdh, Cox4i1, and Hsp90aa1 were determined as biomarkers by five algorithms. Notably, the expression levels of four biomarkers were significantly different in oligodendrocytes and neurons between the PD and CON groups. Subsequently, the pseudotime analysis found that the expression of biomarkers was higher at the end of differentiation in both oligodendrocytes and neurons. What is more, the cell crosstalk between the oligodendrocytes and neurons was high in PD and CON groups. Overall, Ubb, Gapdh, Cox4i1, and Hsp90aa1 were mined as biomarkers, and oligodendrocytes and neurons were key cells in PD patients. Our findings provided new theoretical support for PD treatment.
Indexed as
Identifiers
40537664What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.